SCHEMBL3082219

SCHEMBL3082219

Cc1ccccc1N1CCN(C(=O)CCOc2ccccc2)CC1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.74
MAPT P10636 6/20 0.74
RAB9A P51151 6/20 0.74
SMN1; SMN2 Q16637 5/20 0.74
KMT2A Q03164 3/20 0.74
ALDH1A1 P00352 3/20 0.74
TSHR P16473 2/20 0.74
MAPK1 P28482 2/20 0.74
GAA P10253 4/20 0.64
AR P10275 3/20 0.64
KDM4E B2RXH2 2/20 0.64
HSD17B10 Q99714 1/20 0.55
POLB P06746 1/20 0.55
HPGD P15428 1/20 0.54
ADAMTS5 Q9UNA0 4/20 0.54
MMP1 P03956 1/20 0.53
MEN1 O00255 1/20 0.51
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3076759 0.91 MAPT (0.89) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL3082105 0.87 NPC1 (0.67) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL3081851 0.86 NPC1 (0.65) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL30795903 0.86 NPC1 (0.65) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL3085560 0.82 NPC1 (0.61) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL3084950 0.81 NPC1 (0.60) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL13681487 0.81 NPC1 (0.66) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL15224155 0.81 AR (0.69) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL4075010 0.80 AR (0.76) NPC1MAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL19759012 0.79 ADAMTS5 (0.63) NPC1MAPTRAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100227870-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2010-09-09 US claimed
EP-2164837-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-03-24 EP claimed
WO-2008152089-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-12-18 WO claimed
US-20100227870-A1 Novel Compounds GLAXO GROUP LIMITED (GB) 2010-09-09 US disclosed
EP-2164837-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-03-24 EP disclosed
WO-2008152089-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100227870-A1 Novel Compounds GRM5, GRIK5, GRM1 NPC1 1352/4885MAPT 1435/4885RAB9A 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.